Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET / 6:30am PT MENLO PARK, Calif.
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the appointment of Andrew Sharabi, M.D., Ph.D., as Chief Medical Officer and Chris Krueger, J.D., as Executive Chairman of its Board of Directors. Additionally, Primmune revealed the formation of its Melanoma Clinical Study Advisory Board to support the clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors. “We are thrilled to welcome Dr. Sharabi as Chief Medical Officer. He brings a rare combination of clinical expertise in melanoma, head
Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ISP-002, the company’s investigational therapy for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The FDA grants RPD designation for serious or life-threatening diseases that primarily affect children 18 years old or younger and affect fewer than 200,000 people nationwide. RPD designation allows recipient companies, upon approval of their designated treatment, to be eligible for a Priority Review Voucher (PRV1), which may be used for priority review
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop , trial will focus on early-stage, treatment-naive patients, a key difference from AN2's previous studies in mycobacterium
Orphan Drug Designation for MPS II builds on Immusoft’s clinical progress in MPS I and supports expansion of its engineered B cell platform across multiple indications SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ISP-002, the Company’s investigational engineered B cell therapy for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, a rare and life-threatening lysosomal storage disorder. MPS II is caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), which leads to the progressive accumulation of glycosaminoglycans throughout the body. The disease results in multi-system pathology, including skeletal abnormalities,
Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) First of two boron-based oncology targets to enter development in early 2026 Announced research collaboration with GSK to advance
AN2 awarded third year of funding from Gates Foundation MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom , Co-Founder, Chairman,
The re-dose of ISP-001 has been well-tolerated, to date, and Immusoft continues to observe positive results SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ — Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a patient with a gene modified therapeutic product candidate. The patient in Immusoft’s first-in-human clinical study has now received two doses – separated by 18 months1 – of ISP-001 to treat mucopolysaccharidosis type I (MPS I), with an excellent safety and tolerability profile, to date. Moreover, Immusoft continues to observe positive results in this ongoing clinical trial. This is a momentous event for Immusoft and for the broader gene therapy community, which has long sought the ability to